This study evaluated the clinical efficacy of cyclazocine when used as part of a direct-service drug-abuse program characterized by relatively low-treatment intervention. Standard induction and maintenance schedules were devised and procedures were developed to evaluate results.
Twenty-seven patients were administered cyclazocine over a tenmonth period with 42% being retained. Results suggest that, although cyclazocine was accepted by a majority (75%) of the sample, the nature and extent of side effects during induction may limit its usefulness of a larger scale. The overall program design holds promise as a model for future use of narcotic antagonists.